Trial · NCT01415752
Outcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 26
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) for Induction Phase | Assessed at baseline, every 3 months for 2.5 years, every 6 months up to 10 years from end of treatment, and then annually up to 10 years and 6 months | Eligible and treated patients at Step 1 (induction) | years | MEDIAN |
| PRIMARY | Progression-free Survival (PFS) for Maintenance Phase (Step 2) | Assessed at registration to step 2, cycles 6, 12, 18, treatment completion, then every 3 months for 2.5 years, every 6 months up to 10 years from end of treatment, and then annually up to 10 years and 6 months | Eligible and treated patients at Step 2 (maintenance) | years | MEDIAN |
| SECONDARY | Objective Response for Induction Phase (Step 1) | Assessed at baseline and 24 weeks (end of cycle 6) | Eligible and treated patients at Step 1 (induction) | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | PET-documented Complete Response for Induction Phase (Step 1) | Assessed at baseline and 24 weeks (end of cycle 6) | |||
| SECONDARY | Overall Survival (OS) Rate at 5 Years Since Maintenance (Step 2) | Assessed every 3 months for 2.5 years, every 6 months for years 2.5-5 | Eligible and treated patients for the maintenance phase (Step 2) | Proportion of participants | NUMBER |
| SECONDARY | Objective Response for Maintenance (Step 2) Among Patients Without PET-documented CR at the End of Induction | Assessed at baseline and every 4 months for 2 years | |||
| OTHER_PRE_SPECIFIED | To Collect Paraffin Embedded Tissue for Creation of Tissue Microarray | Assessed at baseline | |||
| OTHER_PRE_SPECIFIED | To Collect and Bank Serum and Blood Mononuclear Cells for Future Studies | Assessed at baseline, end of cycle 3, end of cycle 6, every 4 months during first year of maintenance, every 6 months during 2nd year of maintenance, and 12 months after completion of maintenance | |||
| OTHER_PRE_SPECIFIED | To Collect Formalin Fixed Paraffin Embedded (FFPE) Tissue to Analyze Potential Prognostic Factors | Assessed at baseline | |||
| OTHER_PRE_SPECIFIED | Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT/GOG-Ntx Subscale) Score | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Scale Score | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | Functional Assessment of Cancer Therapy - General (FACT-G) Score | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | To Evaluate the Effects of Bortezomib-related Neuropathy (FACT/GOG-Ntx Subscale Score) on Patient Reported Health-related Quality of Life (FACT-G Score). | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lymphoma) Subscale Score | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | To Evaluate the Response of Lymphoma-specific Symptoms to Treatment. | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | The Trajectory of Overall Health-related Quality of Life | Assessed at baseline, 6, 12, 30, 36, 48 and 60 months | |||
| OTHER_PRE_SPECIFIED | To Assess the Proportion of Patients up and Down Staging When FDGPET/CT is Added to Standard Ann Arbor Staging. | Assessed at baseline and every 4 months for 2 years and every 6 months for years 3-10 and then annually up to 15 years | |||
| OTHER_PRE_SPECIFIED | To Assess the Ability of Pre-treatment FDG-PET/CT Semi Quantitative Parameters Including SUVmax and Metabolic Measurements to Predict Response Rate and PFS. | Assessed at baseline and every 4 months for 2 years and every 6 months for years 3-10 and then annually up to 15 years | |||
| OTHER_PRE_SPECIFIED | Assessment of the Correlation of Interim FDG-PET/CT Imaging With Response Rate and PFS Both During Induction and Consolidation Therapy | Assessed at baseline and every 4 months for 2 years and every 6 months for years 3-10 and then annually up to 15 years | |||
| OTHER_PRE_SPECIFIED | To Assess Standard FDG-PET/CT Metrics and Association With Pathology Features | Assessed at baseline and every 4 months for 2 years and every 6 months for years 3-10 and then annually up to 15 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01415752/outcomes